학술논문
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Document Type
Article
Author
Powles, Thomas ; Plimack, Elizabeth R; Soulières, Denis; Waddell, Tom; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Pouliot, Frédéric; Melichar, Bohuslav; Vynnychenko, Ihor; Azevedo, Sergio J; Borchiellini, Delphine; McDermott, Raymond S; Bedke, Jens; Tamada, Satoshi; Yin, Lina; Chen, Mei; Molife, L Rhoda; Atkins, Michael B; Rini, Brian I
Source
In The Lancet Oncology December 2020 21(12):1563-1573
Subject
Language
ISSN
1470-2045